Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NANT Immunotherapy in Resectable NSCLC
NCT03574649Phase 2Withdrawn
- Sponsor
- ImmunityBio, Inc.
- Start
- Jun 2018
- Primary completion
- Aug 2018
- Modality
- Adenoviral Vectors, Fc-Fusion Proteins, Cancer Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of nogapendekin alfa inbakicept, haNK, aldoxorubicin, ETBX-011, ETBX-051 in non-small cell lung cancer (NSCLC), sponsored by ImmunityBio, Inc.. Planned start Jun 2018; status: withdrawn.
02
Drugs
nogapendekin alfa inbakicepthaNKaldoxorubicinETBX-011ETBX-051
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03574649.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03574649.